JUNIPER PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-10: Form 8-K; Period of report 2015-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-10-20: Form 8-K; Period of report 2015-10-15; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2015-07-22: Form 8-K; Period of report 2015-07-16; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-07-10: Form 8-K; Period of report 2015-07-07; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-10 | 8-K | 2015-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2015, Juniper Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the financial results for the three month period ending September 30, 2015, entitled “Juniper Pharmaceuticals Reports Third Quarter 2015 Financial Results” (the “Press Release”). | d50774d8k.htm |
| 2015-10-20 | 8-K | 2015-10-15 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On October 15, 2015, Juniper Pharmaceuticals, Inc. (the “Company”) entered into a new office lease for its Boston headquarters (the “Lease”) with T-C 33 Arch Street LLC (the “Landlord”) for approximately 7,050 square feet of office space. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | d92875d8k.htm |
| 2015-07-22 | 8-K | 2015-07-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 16, 2015, the Board of Directors (the “Board”) of Juniper Pharmaceuticals, Inc. (the “Company”) appointed Ann Merrifield as a new director of the Company, upon the recommendation of its Nominating & Governance Committee. | d92851d8k.htm |
| 2015-07-10 | 8-K | 2015-07-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As disclosed below under Item 5.07, Ms. Valerie L. Andrews resigned from the board of directors (the “Board”) of Juniper Pharmaceuticals, Inc. (the “Company”), effective July 7, 2015. 5.07 At the 2015 Annual Meeting of Stockholders of the Company held on July 7, 2015, four proposals were submitted to the stockholders of the Company. | d43002d8k.htm |
| 2015-05-28 | 8-K | 2015-05-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 26, 2015, the Board of Directors (the “Board”) of Juniper Pharmaceuticals, Inc. (the “Company”) increased the size of the Board by one member and appointed James Geraghty as a new director of the Company, upon the recommendation of its Nominating and Corporate Governance Committee. | d933383d8k.htm |
| 2015-05-06 | 8-K | 2015-05-06 | 2.02 Results of Operations and Financial Condition | d922346d8k.htm | |
| 2015-04-13 | 8-K | 2015-04-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On April 10, 2015, the Board of Directors of Juniper Pharmaceuticals, Inc. (formerly known as Columbia Laboratories, Inc.) (the “Company”) appointed Dr. Nikin Patel, age 42, as the Company’s new Chief Operating Officer, effective immediately. 8.01 On April 2, 2015, the Company announced that it would change its name to Juniper Pharmaceuticals, Inc. and change its NASDAQ ticker symbol from “CBRX” to “JNP.” The name change became effective on April 10, 2015. | d906254d8k.htm |
| 2015-04-03 | 8-K | 2015-04-02 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On April 2, 2015, Columbia Laboratories, Inc. (“Columbia”) announced that it would change its name to Juniper Pharmaceuticals, Inc. Columbia filed a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) with the Delaware Secretary of State on April 2, 2015 in order to accomplish this change. | d901283d8k.htm |
| 2015-04-01 | 8-K | 2015-03-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d902673d8k.htm |
| 2015-03-18 | 8-K | 2015-03-18 | 2.02 Results of Operations and Financial Condition | d891730d8k.htm | |
| 2015-01-30 | 8-K | 2015-01-28 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 is incorporated herein by reference. 5.02 On January 28, 2015, Stephen G. Kasnet, Chairman of the Board, informed the Board that he has decided not to stand for re-election at the 2015 annual meeting of stockholders (the “2015 Annual Meeting”). 8.01 On January 29, 2015, the Company issued a press release announcing the changes to the Rights Plan described in Item 1.01 of this Current Report on Form 8-K and the decision by the Stephen G. Kasnet, Chairman of the Board, not to stand for reelection to the Board when his current term expires at the 2015 Annual Meeting, as described in Item 5.02 of this Current Report on Form 8-K. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d861777d8k.htm |
| 2015-01-12 | 8-K | 2015-01-09 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On January 9, 2015, the Board of Directors (the “Board”) of Columbia Laboratories, Inc. (the “Company”) approved an amendment to Article I, Section 9 of the Company’s Amended and Restated By-Laws to change the voting standard for uncontested elections of directors to a majority of votes cast from a plurality standard. | d850807d8k.htm |